Clinical Trials Browser

Phase 1/2 × Gliosarcoma × Sorafenib × Clear all

NCT00335764 2018-07-02

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Phase 1/2 Completed

92 enrolled 24 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma